DGIdb - NALTREXONE Drug Record

NALTREXONE chembl:CHEMBL19019 Approved

Alternate Names:

EN-1639A [AS HYDROCHLORIDE]
TREXAL
CELUPAN
VIVITROL
REVIA
TREXAN
EN-1639A
NALTREXONE
EN-1639A FREE BASE
17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
NALTREXONE HCL
N-CYCLOPROPYLMETHYL-14-HYDROXYDIHYDROMORPHINONE
NALTREXON
17-(CYCLOPROPYLMETHYL)-4,5ALPHA-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
NALTREXONA
(-)NALTREXONE
NALTREXONUM
17-(CYCLOPROPYLMETHYL)-4,5Α-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
N-CYCLOPROPYLMETHYLNOROXYMORPHONE
REVIA®
chembl:CHEMBL19019
pubchem.compound:5360515
chemidplus:16590-41-3
drugbank:00704
rxcui:7243

Drug Info:

Drug Indications	for treatment of substance abuse
Drug Class	Small molecule
Drug Indications	appetite suppressant
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	analgesic
Year of Approval	1984
Drug Class	opiate antagonists

(3 More Sources)

Publications:

Kato, 2008, [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence]., Nihon Arukoru Yakubutsu Igakkai Zasshi
Herz, 1998, Opioid reward mechanisms: a key role in drug abuse?, Can. J. Physiol. Pharmacol.
Goodman et al., 2007, Mu opioid receptor antagonists: recent developments., ChemMedChem
Barrios de Tomasi et al., [Opioid antagonists and alcohol consumption]., Rev Neurol
Helm et al., Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification., Pain Physician
Weerts et al., 2008, Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects., Neuropsychopharmacology
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Hendershot CS et al., 2020, OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial., Alcohol Clin Exp Res
Hartwell EE et al., 2020, Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder., Addiction
Roche DJO et al., 2019, Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial., Alcohol Alcohol
Oslin DW et al., 2015, Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial., JAMA Psychiatry
Foulds JA et al., 2015, OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients., Pharmacogenet Genomics
Jonas DE et al., 2014, Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis., Pharmacogenomics
Chamorro AJ et al., 2012, Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis., Addict Biol
Coller JK et al., 2011, OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence., Pharmacogenet Genomics
Ray R et al., 2006, Association of OPRM1 A118G variant with the relative reinforcing value of nicotine., Psychopharmacology (Berl)
Ashenhurst JR et al., 2012, Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol., Pharmacol Biochem Behav
Herz, 1997, Endogenous opioid systems and alcohol addiction., Psychopharmacology (Berl.)
Roy et al., 2005, In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance., J. Neurosci.
Ciampelli et al., 1998, Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus., Horm. Res.
Wee et al., 2009, Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine., Psychopharmacology (Berl.)
San-Emeterio et al., 2006, Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice., Neurosci. Lett.
McCarson et al., 1995, The formalin-induced expression of tachykinin peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration., Neuroscience

NALTREXONE SIGMAR1

Interaction Score: 3.43

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name MorViva

Novel drug target Established target

Trial Name PTI-601

PMIDs:
9040115 19484223 18354714

Sources:
TdgClinicalTrial
NALTREXONE OPRD1

Interaction Score: 2.07

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
22954510 9673788 17661275 9040115 17487229 11752352 15788780

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB
NALTREXONE OPRM1

Interaction Score: 1.49

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
19068776 9673788 17918759 17661275 18354714 17487229 11752352 32020635 31961981 31206155 25760804 25715171 25410894 22515274 21946895 16960700

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB
NALTREXONE DBH

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
NALTREXONE GCG

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9623517

Sources:
NCI
NALTREXONE OPRK1

Interaction Score: 0.91

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
19484223 9040115 17661275 18354714 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND
NALTREXONE TAC1

Interaction Score: 0.7

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7536308

Sources:
NCI
NALTREXONE BAX

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16716514

Sources:
NCI

TEND: NALTREXONE
- Version: 01-August-2011
Alternate Names:

NALTREXONE Primary Drug Name

Drug Info:

Drug Class opiate antagonists

Year of Approval 1984

Publications:
TdgClinicalTrial: NALTREXONE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications analgesic

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: NALTREXONE

Version: 14-September-2017

Alternate Names:

C679 NCI drug code

Drug Info:

Publications:

San-Emeterio et al., 2006, Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice., Neurosci. Lett.

McCarson et al., 1995, The formalin-induced expression of tachykinin peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration., Neuroscience

Ciampelli et al., 1998, Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus., Horm. Res.

PharmGKB: naltrexone

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Ashenhurst JR et al., 2012, Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol., Pharmacol Biochem Behav

Hendershot CS et al., 2020, OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial., Alcohol Clin Exp Res

Hartwell EE et al., 2020, Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder., Addiction

TTD: Naltrexone
- Version: 2020.06.01
Alternate Names:

D0PG8O TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL19019
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL19019
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	MorViva
Novel drug target	Established target
Trial Name	PTI-601

Mechanism of Interaction	Opioid receptors; mu/kappa/delta antagonist
Direct Interaction	yes
Trial Name	ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

NALTREXONE Drug Record

NALTREXONE chembl:CHEMBL19019 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name MorViva Novel drug target Established target Trial Name PTI-601

PMIDs: 9040115 19484223 18354714

Sources: TdgClinicalTrial

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist Direct Interaction yes Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs: 22954510 9673788 17661275 9040115 17487229 11752352 15788780

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs: 19068776 9673788 17918759 17661275 18354714 17487229 11752352 32020635 31961981 31206155 25760804 25715171 25410894 22515274 21946895 16960700

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9623517

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist Direct Interaction yes Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs: 19484223 9040115 17661275 18354714 11752352

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7536308

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16716514

Sources: NCI

TEND: NALTREXONE

Alternate Names: NALTREXONE Primary Drug Name

Drug Info: Drug Class opiate antagonists Year of Approval 1984

Publications:

TdgClinicalTrial: NALTREXONE

Alternate Names:

Drug Info: Drug Indications analgesic Drug Class Small Molecule FDA Approval approved

Publications:

NCI: NALTREXONE

Alternate Names: C679 NCI drug code

Drug Info:

PharmGKB: naltrexone

Alternate Names:

Drug Info:

TTD: Naltrexone

Alternate Names: D0PG8O TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL19019

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL19019

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name MorViva

Novel drug target Established target

Trial Name PTI-601

PMIDs:
9040115 19484223 18354714

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
22954510 9673788 17661275 9040115 17487229 11752352 15788780

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
19068776 9673788 17918759 17661275 18354714 17487229 11752352 32020635 31961981 31206155 25760804 25715171 25410894 22515274 21946895 16960700

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9623517

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
19484223 9040115 17661275 18354714 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
7536308

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16716514

Sources:
NCI

Alternate Names:

NALTREXONE Primary Drug Name

Drug Info:

Drug Class opiate antagonists

Year of Approval 1984

Drug Info:

Drug Indications analgesic

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C679 NCI drug code

Alternate Names:

D0PG8O TTD Drug ID